Format

Send to

Choose Destination
Prim Care Diabetes. 2012 Jul;6(2):127-36. doi: 10.1016/j.pcd.2011.09.003. Epub 2011 Oct 15.

Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.

Author information

1
Department of Health Economics, AstraZeneca Nordic, Astraallén B674, Södertälje, Sweden. ola.granstrom@astrazeneca.com

Abstract

AIM:

The objective of this study was to investigate the cost-effectiveness of saxagliptin (Onglyza(®)), a DPP-4 inhibitor, plus metformin compared with a sulphonylurea (SU) (Glipizide) plus metformin in Swedish patients not well controlled on metformin alone.

METHODS:

Data from a 52-week clinical trial comparing saxagliptin and glipizide in combination with metformin was used in a simulation model to estimate long term complications in a cohort of type 2 diabetes patients. The model estimates the incidence of microvascular and macrovascular complications, diabetes-specific mortality, all-cause mortality, and ultimately, costs and quality-adjusted life years (QALYs) associated with the investigated treatment strategies. Costs and QALYs were estimated for a lifetime time horizon.

RESULTS:

Compared with SU+metformin, the cost per QALY gained with saxagliptin+metformin is approximately SEK 91,000. Patients on saxagliptin+metformin gain 0.10 QALYs on average, at an incremental cost of around SEK 9500. The cost-effectiveness results were robust to various sensitivity analyses.

CONCLUSIONS:

This study demonstrates that, over a patient's lifetime, the addition of saxagliptin to metformin is associated with improvements in quality-adjusted life years compared with SU in patients with type 2 diabetes. Saxagliptin treatment is a cost-effective treatment alternative for type 2 diabetes in patients not well-controlled on metformin alone.

PMID:
22001114
DOI:
10.1016/j.pcd.2011.09.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center